Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Leotta S, Pirosa MC, Markovic U, Scalise L, Bulla A, Sapienza G, Di Giorgio MA, Martino EA, Curto Pelle A, Leotta V, Milone G, Cupri A, Vaddinelli D, Villari L, Conticello C, Milone G. Leotta S, et al. Among authors: bulla a. Chemotherapy. 2019;64(2):110-114. doi: 10.1159/000502473. Epub 2019 Sep 18. Chemotherapy. 2019. PMID: 31533095
Low content of clonogenic progenitors on day+18 is associated with acute graft-versus-host disease and predicts transplant-related mortality.
Milone G, Scirè P, Camuglia MG, Triolo A, Moschetti G, Scuderi MG, Cupri A, Milone GA, Bulla A, Giorgio MAD, Leotta V, Curtopelle A, Sciortino R, Parrinello L, Crocchiolo R, Leotta S. Milone G, et al. Among authors: bulla a. Exp Hematol. 2021 Mar;95:58-67.e4. doi: 10.1016/j.exphem.2021.01.002. Epub 2021 Jan 11. Exp Hematol. 2021. PMID: 33444663 Free article.
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
Markovic U, Romano A, Del Fabro V, Bellofiore C, Bulla A, Parisi MS, Leotta S, Gentile M, Cangialosi C, Vincelli I, Mineo G, Rossi M, Poidomani M, Uccello G, Maugeri C, Mannina D, Innao V, Di Raimondo F, Conticello C. Markovic U, et al. Among authors: bulla a. Front Oncol. 2021 Mar 5;11:624405. doi: 10.3389/fonc.2021.624405. eCollection 2021. Front Oncol. 2021. PMID: 33763359 Free PMC article.
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.
Leotta S, Markovic U, Pirosa MC, Stella S, Tringali S, Martino M, Specchia G, Carluccio P, Risitano AM, Grimaldi F, Vigna E, Palmieri F, Palmieri R, Annunziata M, Pisapia G, Palazzo G, Milone GA, Pelle AC, Scalise L, Di Giorgio MA, Bulla A, Leotta V, Di Raimondo F, Milone G. Leotta S, et al. Among authors: bulla a. Ann Hematol. 2021 Jul;100(7):1743-1753. doi: 10.1007/s00277-021-04504-0. Epub 2021 Mar 28. Ann Hematol. 2021. PMID: 33774681
A Treatment-free Interval Allowed by Ponatinib as Fourth-line Therapy.
Bulla A, Markovic U, Bellofiore C, Stella S, Conticello C, DI Raimondo F, Stagno F. Bulla A, et al. Cancer Diagn Progn. 2021 Mar 3;1(1):19-22. doi: 10.21873/cdp.10003. eCollection 2021 Mar-Apr. Cancer Diagn Progn. 2021. PMID: 35399694 Free PMC article.
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab.
Duminuco A, Romano A, Leotta D, La Spina E, Cambria D, Bulla A, Del Fabro V, Tibullo D, Giallongo C, Palumbo GA, Conticello C, Di Raimondo F. Duminuco A, et al. Among authors: bulla a. Front Oncol. 2023 Mar 29;13:1157610. doi: 10.3389/fonc.2023.1157610. eCollection 2023. Front Oncol. 2023. PMID: 37064138 Free PMC article.
99 results